BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22971455)

  • 1. The safety of testosterone therapy in women.
    Al-Imari L; Wolfman WL
    J Obstet Gynaecol Can; 2012 Sep; 34(9):859-865. PubMed ID: 22971455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
    Kingsberg SA; Simon JA; Goldstein I
    J Sex Med; 2008 Sep; 5 Suppl 4():182-93; quiz 193. PubMed ID: 18783534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of testosterone in the treatment of hypoactive sexual desire disorder.
    Schwenkhagen A; Studd J
    Maturitas; 2009 Jun; 63(2):152-9. PubMed ID: 19359109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
    Davis SR; Braunstein GD
    J Sex Med; 2012 Apr; 9(4):1134-48. PubMed ID: 22304681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
    Krapf JM; Simon JA
    Maturitas; 2009 Jul; 63(3):213-9. PubMed ID: 19487090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Testosterone therapy in female hypoactive sexual desire disorder].
    Meyer P
    Rev Med Suisse; 2016 Mar; 12(510):540-3. PubMed ID: 27149714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone therapy in women: a review.
    Bolour S; Braunstein G
    Int J Impot Res; 2005; 17(5):399-408. PubMed ID: 15889125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.
    Kingsberg S; Shifren J; Wekselman K; Rodenberg C; Koochaki P; Derogatis L
    J Sex Med; 2007 Jul; 4(4 Pt 1):1001-8. PubMed ID: 17627745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies.
    Braunstein GD
    J Sex Med; 2007 Jul; 4(4 Pt 1):859-66. PubMed ID: 17627735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case series of androgen use in breast cancer survivors with sexual dysfunction.
    Krychman ML; Stelling CJ; Carter J; Hudis CA
    J Sex Med; 2007 Nov; 4(6):1769-74. PubMed ID: 17666036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone supplementation for hypoactive sexual desire disorder in women.
    Woodis CB; McLendon AN; Muzyk AJ
    Pharmacotherapy; 2012 Jan; 32(1):38-53. PubMed ID: 22392827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?
    Schover LR
    Fertil Steril; 2008 Jul; 90(1):129-40. PubMed ID: 18023435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
    Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L
    J Sex Med; 2021 May; 18(5):849-867. PubMed ID: 33814355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder.
    White WB; Grady D; Giudice LC; Berry SM; Zborowski J; Snabes MC
    Am Heart J; 2012 Jan; 163(1):27-32. PubMed ID: 22172433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens and Psychosocial Factors Related to Sexual Dysfunctions in Premenopausal Women
    Wåhlin-Jacobsen S; Kristensen E; Pedersen AT; Laessøe NC; Cohen AS; Hougaard DM; Lundqvist M; Giraldi A
    J Sex Med; 2017 Mar; 14(3):366-379. PubMed ID: 28117267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women.
    Palacios S
    Womens Health (Lond); 2011 Jan; 7(1):95-107. PubMed ID: 21175394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
    Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L
    Climacteric; 2021 Dec; 24(6):533-550. PubMed ID: 33792440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menopause and sexual desire: the role of testosterone.
    Nappi RE; Albani F; Santamaria V; Tonani S; Martini E; Terreno E; Brambilla E; Polatti F
    Menopause Int; 2010 Dec; 16(4):162-8. PubMed ID: 21156854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study.
    Panay N; Al-Azzawi F; Bouchard C; Davis SR; Eden J; Lodhi I; Rees M; Rodenberg CA; Rymer J; Schwenkhagen A; Sturdee DW
    Climacteric; 2010 Apr; 13(2):121-31. PubMed ID: 20166859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis.
    Achilli C; Pundir J; Ramanathan P; Sabatini L; Hamoda H; Panay N
    Fertil Steril; 2017 Feb; 107(2):475-482.e15. PubMed ID: 27916205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.